ObsEva (NASDAQ:OBSV) Now Covered by Analysts at Canaccord Genuity Group

Canaccord Genuity Group began coverage on shares of ObsEva (NASDAQ:OBSVGet Rating) in a research note issued to investors on Tuesday, The Fly reports. The firm set a “buy” rating and a $12.00 price target on the stock.

A number of other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of ObsEva from a “hold” rating to a “sell” rating in a report on Thursday, March 31st. Aegis assumed coverage on shares of ObsEva in a report on Monday, March 28th. They issued a “buy” rating and a $12.00 price target for the company. Canaccord Genuity Group assumed coverage on shares of ObsEva in a report on Tuesday. They issued a “buy” rating and a $12.00 price target for the company. StockNews.com raised shares of ObsEva from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. Finally, HC Wainwright decreased their price objective on shares of ObsEva from $15.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, March 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $11.88.

OBSV opened at $1.58 on Tuesday. The firm’s 50-day moving average is $1.34. ObsEva has a 52 week low of $1.08 and a 52 week high of $3.58. The company has a market cap of $123.19 million, a P/E ratio of -2.00 and a beta of 0.73. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.70 and a quick ratio of 2.70.

ObsEva (NASDAQ:OBSVGet Rating) last released its quarterly earnings data on Thursday, March 10th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.04). As a group, analysts forecast that ObsEva will post -1.14 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new stake in ObsEva in the fourth quarter worth about $44,000. Dimensional Fund Advisors LP purchased a new position in shares of ObsEva during the fourth quarter worth approximately $62,000. GSA Capital Partners LLP purchased a new position in shares of ObsEva during the third quarter worth approximately $100,000. Cubist Systematic Strategies LLC increased its position in shares of ObsEva by 270.9% during the fourth quarter. Cubist Systematic Strategies LLC now owns 41,201 shares of the company’s stock worth $82,000 after acquiring an additional 30,094 shares during the period. Finally, Toroso Investments LLC purchased a new position in shares of ObsEva during the third quarter worth approximately $199,000. 22.28% of the stock is owned by institutional investors and hedge funds.

About ObsEva (Get Rating)

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Further Reading

The Fly logo

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.